Wells Fargo & Company MN Reduces Holdings in Genmab A/S (NASDAQ:GMAB)

Wells Fargo & Company MN lowered its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 59.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 283,111 shares of the company's stock after selling 417,293 shares during the period. Wells Fargo & Company MN's holdings in Genmab A/S were worth $5,909,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC grew its position in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, R Squared Ltd bought a new stake in shares of Genmab A/S during the fourth quarter worth $93,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Up 1.6 %

Genmab A/S stock traded up $0.32 during trading hours on Thursday, reaching $20.45. 279,111 shares of the company's stock were exchanged, compared to its average volume of 1,043,818. The firm's 50 day simple moving average is $20.51 and its 200 day simple moving average is $21.10. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.41. The firm has a market capitalization of $13.53 billion, a PE ratio of 11.75, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on GMAB shares. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.